Covid-19 roundup: CureVac backs out of manufacturing contracts as demand dwindles; Despite PhII/III flop, biotech keeps looking for silver lining
CureVac terminated contracts with two companies who had signed on to help the German drug maker manufacture its mRNA Covid-19 vaccine in Europe, as potential demand for its shot has dwindled.
Contracts with Wacker for the manufacturing of mRNA drug substance and Celonic for the manufacturing and formulation of the mRNA drug substance for the drug, dubbed CVnCoV, are no more. The company has held on to existing agreements with Rentschler Biopharma and Novartis for mRNA production, and said that those will not be affected.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.